Universe Pharmaceuticals Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Universe Pharmaceuticals Inc Universe Pharmaceuticals INC (NASDAQ:UPC), through its subsidiaries, engages in the manufacturing, marketing, distribution, and sale of traditional Chinese medicine derivative products in China, targeting elderly consumers to address aging-related physical conditions and promote general well-being; its core offerings include chronic condition treatments such as Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal Liquor, alongside cold and flu medications like Paracetamol Granule for Children and Isatis Root Granule. The company also distributes third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements, serving pharmaceutical companies, hospitals, clinics, and drugstore chains primarily within China. Founded in 1998 and headquartered in Ji'an, China, Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited. In recent developments, the company implemented a 15:1 share consolidation effective November 12, 2024, followed by a 40:1 consolidation effective March 24, 2025, to meet Nasdaq listing requirements and adjust its share structure with a new par value of US$11.25; additionally, it completed a self-underwritten public offering on July 15, 2024, raising $25 million before expenses to support online sales channels and digital marketing strategies for brand expansion.
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology
Universe Pharmaceuticals (NASDAQ:UPC) Stock Price Down 2.4% – Time to Sell?
Financial Contrast: Universe Pharmaceuticals (NASDAQ:UPC) versus Jaguar Animal Health (NASDAQ:JAGX)
Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure
Head-To-Head Review: Universe Pharmaceuticals (NASDAQ:UPC) and NRx Pharmaceuticals (NASDAQ:NRXP)
Critical Review: Centessa Pharmaceuticals (NASDAQ:CNTA) & Universe Pharmaceuticals (NASDAQ:UPC)
Universe Pharmaceuticals INC Announces Share Consolidation
Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report
Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request
Univest Securities, LLC Announces Closing of $15 Million Registered Direct Offering for its Client Universe Pharmaceuticals INC (NASDAQ: UPC)
Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
“I Will Make UPC Great Again!”—UPC Presidential Hopeful Othieno Vows as He Praises Obote’s Legacy
Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024
UPC Tasks President Museveni to Produce Evidence of Vote Rigging in Courts of Law
UPC Concerned over Welfare of Medical Interns
UPC Calls on Government to Impact Skills Development Education in Youth
UPC Raises Red Flag on Road Carnage, City Robberies
UPC Condemns Re- Arrest of Legislator Released on Bail for Corruption Charges